Evidence map›Paper›PMID 19275541›Full record

ReviewCurrent drug discovery technologies2009

Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect.

Hari Krishna Sajja, Michael P East, Hui Mao, Y Andrew Wang, Shuming Nie, Lily Yang

Abstract readReview
In one paragraph

Review in Current drug discovery technologies, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Precision Oncology: Advances in Drug Delivery and Imaging.Recent advances in drug delivery and formulation · 2025
    Review
  2. Emerging Nanomedicine Approaches in Targeted Lung Cancer Treatment.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.American journal of clinical and experimental urology · 2022
    Review
  15. Review
  16. Hyaluronan-Metal Gold Nanoparticle Hybrids for Targeted Tumor Cell Therapy.International journal of molecular sciences · 2020
    Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hari Krishna SajjaDepartment of Surgery and Winship Cancer Institute, Emory University School of Medicine, Room C-4088, 1365-C Clifton Road, Atlanta, GA 30322, USA.
Michael P East
Hui Mao
Y Andrew Wang
Shuming Nie
Lily Yang

Funding

Tissue and Animal UseU54CA119338 · NCI · EMORY UNIVERSITY · PI BAO, GANG · 2005 to 2009
$18.4M
TARGETING DEATH RECEPTOR-MEDIATED APOPTOSIS FOR HEAD AND NECK CANCERP50CA128613 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2007 to 2011
$12.0M
Nanotechnology Linking Biomarkers with Cancer BehaviorR01CA108468 · NCI · EMORY UNIVERSITY · PI NIE, SHUMING · 2004 to 2008
$6.9M
Nanotechnology for Multiplexed and Intraoperative Cancer DetectionRC2CA148265 · NCI · EMORY UNIVERSITY · PI NIE, SHUMING · 2009 to 2010
$2.0M
Targeted Nanoprobes For Intraoperative optical Imaging of Breast Cancer MarginsR01CA133722 · NCI · EMORY UNIVERSITY · PI YANG, LILY · 2008 to 2012
$1.6M
IAPs As Novel Targets for Cancer TherapyR01CA095643 · NCI · EMORY UNIVERSITY · PI YANG, LILY · 2003 to 2007
$1.2M
NCI NIH HHS P50 CA128613NCI NIH HHS R01 CA095643NCI NIH HHS R01 CA108468NCI NIH HHS R01 CA133722NCI NIH HHS R01CA133722NCI NIH HHS R01-CA95643NCI NIH HHS RC2 CA148265NCI NIH HHS U54 CA119338NCI NIH HHS U54 CA119338-01
6 · The paper itself

Abstract

Nanotechnology is a multidisciplinary scientific field undergoing explosive development. Nanometer-sized particles offer novel structural, optical and electronic properties that are not attainable with individual molecules or bulk solids. Advances in nanomedicine can be made by engineering biodegradable nanoparticles such as magnetic iron oxide nanoparticles, polymers, dendrimers and liposomes that are capable of targeted delivery of both imaging agents and anticancer drugs. This leads toward the concept and possibility of personalized medicine for the potential of early detection of cancer lesions, determination of molecular signatures of the tumor by noninvasive imaging and, most importantly, molecular targeted cancer therapy. Increasing evidence suggests that the nanoparticles, whose surface contains a targeting molecule that binds to receptors highly expressed in tumor cells, can serve as cancer image contrast agents to increase sensitivity and specificity in tumor detection. In comparison with other small molecule contrast agents, the advantage of using nanoparticles is their large surface area and the possibility of surface modifications for further conjugation or encapsulation of large amounts of therapeutic agents. Targeted nanoparticles ferry large doses of therapeutic agents into malignant cells while sparing the normal healthy cells. Such multifunctional nanodevices hold the promise of significant improvement of current clinical management of cancer patients. This review explores the development of nanoparticles for enabling and improving the targeted delivery of therapeutic agents, the potential of nanomedicine, and the development of novel and more effective diagnostic and screening techniques to extend the limits of molecular diagnostics providing point-of-care diagnosis and more personalized medicine.

Indexed as

Drug Delivery SystemsNanoparticlesAnimalsAntineoplastic AgentsBiomarkers, TumorHumansNanomedicineNeoplasmsAntineoplastic AgentsBiomarkers, Tumor

Identifiers

PMID19275541
PMCPMC3108242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.